Sorry! Sendingen går på gruppa “aksjeforum”
Litt artig at det står +Infinty% på dagens stigning i tickeren til høyre på siden her. Innsideinformasjon @pdx? 
1 Like
Ja, det er morgendagens kurs 
Løp og kjøp
Er nok en liten bug fra Yahoo Finance der kursene kommer fra.
2 Likes
4 Likes
Håper DNM snart er ferdig med nedsalget. Liker ikke når DNM er party poop i aksjene jeg eier. 
1 Like
3 Likes
kommentar 11:48 - 24.03.2017
Geir Linløkken
Geir Linløkken er analyse- og forskningssjef hos Investtech.
Targovax ble tatt opp på Oslo Børs hovedliste i går.
Aksjen har steget 124 prosent siden nyttår. Targovax gjorde det sterkt også i fjor og ligger i en fin stigende trendkanal på mellomlang sikt. Dette viser at investorene stadig går høyere i pris for å kjøpe seg inn i aksjen og indikerer at bedriften opplever en lovende kommersiell utvikling.
Volumutviklingen er også positiv og en videre oppgang indikeres.
Ved reaksjoner tilbake er det støtte ved 24,50 kroner på kort sikt.
Høy risiko.
Anbefaling kort sikt: Kjøp
ref: http://e24.no/kommentarer/investtech-skal-disse-tre-kursrakettene-fortsette-opp/23957666
3 Likes
Er det et liten periode med nyhetstørke(q1 i mai neste?), fallende olje og usikkerhet i forhold til emmisjon som er det fundamentale som styrer nå?
Den ser gunstig ut i dag, men tenker det kanskje ikke er riktig tid for innkjøp enda?
1 Like
Jeg skjønner ikke helt hvorfor aksjen føk videre fra 22-24 i utgangspunktet må jeg innrømme, det var jo allerede et massivt hopp opp fra 11.
2 Likes
Sikkert mange som ikke klarer å fatte at nano har gått fra 10 til 85kr. Oppsiden er eventyrlig stor om targo får samme reise som nano i 2017.
1 Like
Absolutt. Men det var penger og data som kjørte oppturen til NANO, og vi venter fremdeles på de to i Targovax.
3 Likes
Dog, markedet bruker gjerne en måned på å prise data riktig.
Top shareholders på hjemmesiden per 02.04.17, men står ikke når det er oppdatert:
Vanvittig innslag av aksjefond på topp 20.
Largest Shareholders
Investor Number of Shares % of top 20 % of total Type Country
HEALTHCAP V LP 10989402 41.54% 26.04% COMP SWE
RADIUMHOSPITALETS 4077255 15.41% 9.66% COMP NOR
NORDNET LIVSFORSIKRING AS 1419268 5.37% 3.36% COMP NOR
VPF NORDEA AVKASTNING 1196582 4.52% 2.84% COMP NOR
VPF NORDEA KAPITAL 1046754 3.96% 2.48% COMP NOR
KLP AKSJENORGE 934415 3.53% 2.21% COMP NOR
DANSKE BANK A/S 740822 2.80% 1.76% NOM DNK
TIMMUNO AS 724650 2.74% 1.72% COMP NOR
PRIETA AS 720000 2.72% 1.71% COMP NOR
STATOIL PENSJON 668916 2.53% 1.59% COMP NOR
KOMMUNAL LANDSPENSJONSKASSE 653660 2.47% 1.55% COMP NOR
NORDNET BANK AB 639203 2.42% 1.51% NOM SWE
PORTIA AS 400000 1.51% 0.95% COMP NOR
VERDIPAPIRFONDET NORDEA NORGE PLUS 395903 1.50% 0.94% COMP NOR
NORDEA 1 SICAV 384579 1.45% 0.91% COMP LUX
CRESSIDA AS 350000 1.32% 0.83% COMP NOR
SUNDT AS 300000 1.13% 0.71% COMP NOR
VIOLA AS 300000 1.13% 0.71% COMP NOR
THORENDAHL INVEST AS 260000 0.98% 0.62% COMP NOR
AVANZA BANK AB 251448 0.95% 0.60% NOM SWE
Total number owned by top 20 26452857
Total number of shares 42199719
Tror jeg husker hvorfor. Det var emisjonsaksjer som holdt prisen i TRVX nede gjennom hele høsten. Hadde innkjøp på 7,7x, og gikk lei av nedsalget og dødgangen. Den ville nok vært i 11+ en del tidligere om ikke dette nedsalget hindret. At den skulle høyt over 24 så jeg ikke komme. Kontaktet noen for å tipse på salg ved 28. Kanskje biotek i vinden i år som er svaret?
Er det Targo som skal gå litt i dag?
Kunne tenkt meg å solgt nok i Fun for å kjøpe 5k i Targo…
Oslo, Norway, 6 April 2017: Targovax ASA (“Targovax” or “the Company”; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target treatment-resistant solid tumors, today announces that clinical data from the phase I/II clinical trial evaluating TG01 in resected pancreatic cancer will be presented at the American Society of Clinical Oncology (‘ASCO’) Annual Meeting 2017 at McCormick Place in Chicago, Illinois, 2-6 June 2017.
The abstract title will be released on 20 April and the abstract will be released on 17 May on abstracts.asco.org.
Please see the press release dated 2 February 2017 for more information.
1 Like
Min teori er at NANO og PCIB kommer til å være i fokus frem mot siste halvpart av Mai - så begynner folk å omplassere deler av porteføljen til TRVX. Det er min plan også.
3 Likes
Opsjonsfest i TRVX
Ikke småsummer de får i opsjoner her, CEO kommer best ut, her er et utdrag.
The
exercise price of the options is NOK 21.96.
A total of 770,000 options for shares of the
Company were distributed amongst the members of the executive management and a
total of 295,000 options for shares of the Company were distributed amongst
other employees.
Chief Executive Officer Øystein Soug has been granted 250,000 share options.
Following the grant, he holds 100,000 shares and 790,000 options in the Company.
hele meldingen:
http://www.newsweb.no/newsweb/search.do?messageId=424393
Har stor tro på denne i løpet av året.
Som det meste har også kursen falt noe tilbake. Befinner seg nå i «tidligere» range igjen rent teknisk. Motstand ved 24,90 kr her og støtte rundt 21,90. Brytes motstand her er neste motstandsnivå først ved 31 kr, nå som en etterhvert har fått mer erfaringsdata å bygge TA på.
Fundamentalt er «odds» styrket etter så langt positive meldinger rundt selskapets forskningsresultater. Vi nærmer oss nyheter her som igjen forventes å ha betydelig kurseffekt opp/ned etter hva nyheter indikerer. Selskapet er finansiert til og med q1 18 slik at emisjonsrisiko er liten p.t.
Kursmålet mitt er 48 kr etter sommeren, langt fra urealistisk når en sammenlikner med annen Biotech/farma. Dette forutsetter som nevnt fortsatt positive meldinger, hvor slik jeg ser det «odds» er styrket etter tidligere melding.
3 Likes
First patient enrolled in a Phase Ib trial in patients with locally recurrent
RAS-mutated rectal cancer
Oslo, 20 April 2017: Targovax ASA (“Targovax” or “the Company”; OSE: TRVX), a
clinical stage company focused on developing immuno-oncology therapies to target
solid tumors, announces that it has recruited the first patient in an
exploratory Phase Ib clinical trial of TG02 in patients with locally recurrent
RAS-mutated rectal cancer scheduled to have surgery. The trial is being
conducted at clinical sites in Australia and New Zealand.
In this open label, non-randomized trial, ten patients will receive TG02 as
monotherapy and then followed by ten patients receiving TG02 in combination with
pembrolizumab, a PD-1 checkpoint inhibitor. The trial’s primary objective is to
investigate the safety and immune activity in peripheral blood and at the tumor
level.
TG02 is the second TG cancer immune activator to enter the clinic from the
Company’s peptide-based immunotherapy platform. It contains a proprietary
mixture of eight synthetic peptides representing fragments of the most frequent
RAS mutations seen in rectal cancer. Studies to date have shown that the
Company’s lead immune activator for RAS-mutated cancer, TG01, induces immune
responses in cancer patients with resected pancreatic cancer, which may
translate clinically to a survival benefit.
Mutations in RAS, a family of structurally related proteins that regulate cell
growth, are seen in about 50% of colorectal cancers, and nearly all patients
with recurrent disease. They are associated with a limited response to
chemotherapy and poor prognosis. Previous and ongoing clinical studies have
shown that TG peptides are able to induce RAS mutation specific immune
responses. Targovax is the only company with RAS-mutated specific immune
activators in clinical development.
Magnus Jaderberg MD, Chief Medical Officer at Targovax said, “We are excited to
have initiated this study in patients with locally recurring RAS-mutated rectal
cancer. This will be the first time our TG02 immune activator will be tested in
humans and, while the study’s primary objective is to study safety, we will also
be looking at signs of anti-tumour immune activation, thus providing important
mechanistic data not just for TG02 but for the entire TG technology platform. In
addition, it will give us an indication on how this novel immunotherapy can be
enhanced in combination with a checkpoint inhibitor.”
For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: [email protected]
Media and IR enquires:
Jan Petter Stiff - Crux Advisers (Norway)
Phone: +47 995 13 891
Email: [email protected]
Julia Phillips/Simon Conway - FTI Consulting (International)
Phone: +44 20 3727 1000
Email: [email protected]
About Targovax
Arming the patient’s immune system to fight cancer
Targovax is a clinical stage company focused on developing and commercializing
novel immuno-oncology therapies to target, primarily, treatment-resistant solid
tumors. Immuno-oncology is currently one of the fastest growing therapeutic
fields in medicine.
The Company’s development pipeline is based on two novel proprietary platforms:
The first platform, ONCOS, uses oncolytic viruses, an emerging class of
biological therapy. ONCOS exclusively uses an adenovirus that has been
engineered to be a tumor-targeted immune activator. The platform has the
potential to generate therapies with superior efficacy and safety compared to
the first approved oncolytic virus therapy, Imlygic(®), launched by Amgen. We
continue to expect key proof of concept data for this platform in 2017 from a
clinical study of lead program ONCOS-102 in patients with refractory malignant
melanoma.
The second platform, TG peptides (TG), solely targets tumors that express
mutated forms of the RAS protein. Mutations to this protein are common in many
cancers and are known to drive aggressive disease progression and treatment
resistance. There is a high unmet medical need for therapies that are effective
against tumors that express these mutations. The TG platform’s therapeutic
potential stems from its ability to enable a patient’s immune system to identify
and then destroy tumors bearing any RAS mutations. In early 2017, key proof of
concept data for the TG platform from a clinical study of TG01 in resected
pancreatic cancer patients showed encouraging overall survival and will give
guidance for the future clinical development of this platform.
Targovax’s development pipeline has three novel therapeutic candidates in
clinical development covering six indications.
Both platforms are protected by an extensive portfolio of IP and know-how and
have the potential to yield multiple product candidates in a cost-effective
manner. Additionally, we have other products in early stages of development.
In July 2016, the Company listed its shares on Oslo Axess. In March 2017, the
shares were upgraded to Oslo Børs, the main Oslo Stock Exchange.
This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.
4 Likes